Gallic acid enhances pirarubicininduced anticancer in living K562 and K562/Dox leukemia cancer cells through cellular energetic state impairment and Pglycoprotein inhibition.
Oncol Rep
; 46(4)2021 Oct.
Article
in En
| MEDLINE
| ID: mdl-34476509
Leukemia is a common malignancy affecting humans worldwide. Pirarubicin (Pira) is one of the anticancer agents used for the treatment of leukemia. Although Pira is effective, drug resistance may develop in cancer cells exposed to this drug, whereas the combination of natural products with Pira may help to overcome this problem. The aim of the present study was to focus on the effect of gallic acid (GA) on the anticancer activity of Pira in K562 leukemia cells and K562/doxorubicin (Dox)resistant leukemia cells in order to investigate the possible underlying mechanisms. The cell viability, mitochondrial activity, mitochondrial membrane potential (ΔΨm) and ATP levels were assessed in living K562 and K562/Dox cancer cells following treatment with GA/Pira combination, GA alone or Pira alone. Pglycoproteinmediated efflux of Pira was determined in GAtreated K562/Dox cancer cells. The results demonstrated that GA/Pira combination decreased cell viability, mitochondrial activity, ΔΨm and ATP levels in K562 and K562/Dox cancer cells in a GA concentrationdependent manner compared with nontreated or Piratreated cells. GA inhibited Pglycoproteinmediated efflux of Pira in GAtreated K562/Dox cancer cells. Therefore, GA enhanced the anticancer effect of Pira on K562 and K562/Dox cancer cells through cellular energy status impairment, and was able to reverse drug resistance in living K562/Dox cancer cells by inhibiting the function of Pglycoprotein.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Leukemia
/
Doxorubicin
/
Cell Survival
/
ATP Binding Cassette Transporter, Subfamily B, Member 1
/
Drug Resistance, Neoplasm
/
Gallic Acid
Limits:
Humans
Language:
En
Journal:
Oncol Rep
Year:
2021
Document type:
Article